Solopharm has achieved significant success, taking first place in the Russian ophthalmological market by volume at the end of 2024. According to analytical companies IQVIA (Retail + Contracts 44FZ) and HeadWay (Ophthalmic Surgery), Solopharm became the leader in the segment of ophthalmic drugs and products, including medicinal products, medical devices, and ophthalmic surgical products.
The company's assortment covers a wide range of ophthalmic solutions: eye drops, lens solutions, ophthalmic solutions, viscoelastic devices, and other forms. This success confirms Solopharm's commitment to high-quality standards and innovation in ophthalmology.
Solopharm expresses gratitude to the medical community and patients for their trust and support, which contributed to this achievement. The company continues to strive for the development and implementation of advanced solutions for preserving and improving patients' vision.